Immune checkpoint binding assays are essential for evaluating interactions between checkpoint proteins and their ligands. These assays help determine binding affinity, specificity, and inhibitory effects, supporting cancer immunotherapy development. Techniques such as ligand binding assays, cell-based binding assays, and functional reporter gene assays provide insights into immune modulation. By optimizing binding assays, researchers can enhance precision medicine, ensuring effective immune checkpoint targeting for improved therapeutic outcomes.